Literature DB >> 11704771

[Prevalence of primary Helicobacter pylori resistance to eight antimicrobial agents in a hospital in Madrid].

C Toro1, J García-Samaniego, J Carbó, A Iñiguez, T Alarcón, M López-Brea, M Baquero.   

Abstract

The aim of this study was to determine the prevalence of primary Helicobacter pylori resistance, and to investigate the relationship with factors such as age and sex. During 1998, 106 H. pylori strains collected from dyspeptic patients who had had no previous H. pylori treatment were studied. The minimun inhibitory concentrations of metronidazole, amoxicillin, clarithromycin, tetracycline, azithromycin, clindamycin, cefotaxime and ciprofloxacin were determined by E-test.((R)). The overall prevalence of primary metronidazole resistance was 40.6%. Although it was more frequent in women than in men (44.4% vs. 37.7%), the difference was significant only in the women who were under 45 years of age. For the rest of the antibiotics, the primary resistance rates were the following: clarithromycin 9.5%, azithromycin 10.3%, clindamycin 13.1%, and ciprofloxacin 7.9%. No resistance to tetracycline and b-lactam antibiotics was found. Clarithromycin and amoxicillin were the most active compounds of the macrolides and b-lactams studied, respectively.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11704771

Source DB:  PubMed          Journal:  Rev Esp Quimioter        ISSN: 0214-3429            Impact factor:   1.553


  8 in total

1.  Quinolone resistance in Helicobacter pylori isolates in Germany.

Authors:  Erik Glocker; Hans-Peter Stueger; Manfred Kist
Journal:  Antimicrob Agents Chemother       Date:  2006-10-16       Impact factor: 5.191

2.  Gatifloxacin resistance and mutations in gyra after unsuccessful Helicobacter pylori eradication in Japan.

Authors:  Toshihiro Nishizawa; Hidekazu Suzuki; Kumiko Kurabayashi; Tatsuhiro Masaoka; Hiroe Muraoka; Mikiji Mori; Eisuke Iwasaki; Intetsu Kobayashi; Toshifumi Hibi
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

3.  Single and double mutations in gyrA but not in gyrB are associated with low- and high-level fluoroquinolone resistance in Helicobacter pylori.

Authors:  Jacques Tankovic; Christine Lascols; Quentin Sculo; Jean-Claude Petit; Claude-James Soussy
Journal:  Antimicrob Agents Chemother       Date:  2003-12       Impact factor: 5.191

4.  Quinolone-Based Third-Line Therapy for Helicobacter pylori Eradication.

Authors:  Toshihiro Nishizawa; Hidekazu Suzuki; Toshifumi Hibi
Journal:  J Clin Biochem Nutr       Date:  2009-02-28       Impact factor: 3.114

5.  Isolation of Helicobacter pylori in gastric mucosa and susceptibility to five antimicrobial drugs in Southern chile.

Authors:  Laura Otth; Myra Wilson; Heriberto Fernández; Carola Otth; Claudio Toledo; Victoria Cárcamo; Paula Rivera; Luis Ruiz
Journal:  Braz J Microbiol       Date:  2011-06-01       Impact factor: 2.476

6.  Resistance to amoxicillin, clarithromycin and ciprofloxacin of Helicobacter pylori isolated from Southern Brazil patients.

Authors:  Simone Ulrich Picoli; Luiz Edmundo Mazzoleni; Heriberto Fernández; Laura Renata De Bona; Erli Neuhauss; Larisse Longo; João Carlos Prolla
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2014 May-Jun       Impact factor: 1.846

7.  Evaluation of the benefit of addition of clidinium C to a Helicobacter pylori eradication regimen.

Authors:  Maryam Chorami; Homayoun Zojaji; Nosratollah Naderi; Bijan Moghimi-Dehkordi; Dariush Mirsattari; Hamid Mohaghegh Shalmani
Journal:  Gastroenterol Hepatol Bed Bench       Date:  2013

8.  Crystal structure confirmation of JHP933 as a nucleotidyltransferase superfamily protein from Helicobacter pylori strain J99.

Authors:  Yanhe Zhao; Xianren Ye; Yintao Su; Lifang Sun; Feifei She; Yunkun Wu
Journal:  PLoS One       Date:  2014-08-07       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.